Untangling the Gordian knot of HIV, stress, and cognitive impairment  by Valdez, Arielle N. et al.
lable at ScienceDirect
Neurobiology of Stress 4 (2016) 44e54Contents lists avaiNeurobiology of Stress
journal homepage: http : / /www.journals .e lsevier .com/neurobiology-of-stress/Untangling the Gordian knot of HIV, stress, and cognitive impairment
Arielle N. Valdez a, b, Leah H. Rubin c, Gretchen N. Neigh d, e, *
a Emory University Medical Scientist Training Program, USA
b Emory University Department of Cell Biology, USA
c Univeristy of Illinois at Chicago, Department of Psychiatry, USA
d Emory University Department of Physiology, USA
e Emory University Department of Psychiatry & Behavioral Sciences, USAa r t i c l e i n f o
Article history:
Received 20 November 2015
Received in revised form
4 February 2016
Accepted 9 February 2016
Available online 11 February 2016
Keywords:
HIV
Stress
Inﬂammation
CD4
CognitionAbbreviation: IL-1b, Interleukin-1b; IL-2, Interleuk
quired immune deﬁciency syndrome; ANI, Asymptom
Central Nervous System; CRP, C-reactive protein; GAL
Non-AIDS; HAND, HIV-associated neurocognitive diso
INSTIs, Integrase strand transfer inhibitors; LPS, Lipo
transcriptase inhibitors; NRTIs, Nucleoside reverse tran
stress disorder; ROS, Reactive oxygen species; TNFa,
* Corresponding author. Virginia Commonwealth U
E-mail address: gretchen.mccandless@vcuhealth.o
http://dx.doi.org/10.1016/j.ynstr.2016.02.005
2352-2895/© 2016 The Authors. Published by Elseviera b s t r a c t
As individuals live longer with HIV, this “graying of the HIV epidemic” has introduced a new set of
challenges including a growing number of age and inﬂammation-related diseases such as cardiovascular
disease, type II diabetes, cancer, and dementia. The biological underpinnings of these complex and co-
morbid diseases are not fully understood and become very difﬁcult to disentangle in the context of
HIV and aging. In the current review we examine the contributions and interactions of HIV, stress, and
cognitive impairment and query the extent to which inﬂammation is the linchpin in these dynamic
interactions. Given the inter-relatedness of stress, inﬂammatory mechanisms, HIV, and cognitive
impairment, future work will either need to address multiple dimensions simultaneously or embrace the
philosophy that breaking the aberrant cycle at any one point will subsequently remedy the other related
systems and processes. Such a single-point intervention may be effective in early disease states, but after
perpetuation of an aberrant cycle, adaptations in an attempt to internally resolve the issue will likely lead
to the need for multifaceted interventions. Acknowledging that HIV, inﬂammation, and stress may
interact with one another and collectively impact cognitive ability is an important step in fully under-
standing an individual's complete clinical picture and moving towards personalized medicine.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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With increasing efﬁcacy of antiretroviral therapy (ART), HIV has
shifted from a disease with high mortality to a chronic disease with
substantial longevity. By 2015, over half of people living with HIV
(PLWH) will be aged 50 or older. This increase in age among those
living with HIV has been referred to as the “graying of the HIV
epidemic” and has introduced a new set of challenges including a
growing number of age and inﬂammation-related diseases such as
cardiovascular disease, type II diabetes, cancer, and dementia (High
et al., 2012). The contribution of persistent immune activation and
inﬂammation to HIV-associated, Non-AIDS (HANA) conditions in
PLWH who are on adequate ART (Hunt, 2012) has garnered
increased attention as these may fuel neurocognitive complications
of the disease (Hong and Banks, 2015) which hinder daily func-
tioning (Heaton et al., 2004). Despite the well-established inﬂam-
matory consequences of HIV, the perpetuating force behind
sustained inﬂammation in otherwise healthy PLWH has not been
identiﬁed. While the cellular and molecular mechanisms underly-
ing the interaction between residual immune activation/inﬂam-
mation and residual neurological disease are not well deﬁned, a
robust literature demonstrates a substantial impact of stress
exposure on inﬂammation, immune activation, and cognitive
function. Furthermore, HIV appears to interact with or accelerate
age-related inﬂammation (Zapata and Shaw, 2014) leading to an
exaggerated impact on both somatic systems (e.g., cardiovascular
disease) and the central nervous system (CNS; e.g., neurocognitive
impairment), which may produce a feed-forward cycle (Nemeth
et al., 2014).
The interactions of stress with chronic complex disease states
and aging generate a mechanistic quagmire making it difﬁcult to
isolate, study, and develop an understanding of the underlying
pathology. Such stalemates halt treatment advances and conjure
images of the legendary Gordian knot from Greek mythology. In
this ancient story, King Gordius of Phrygia tied a complicated knot,
which no one could make loose, until Alexander the Great cut it
with his sword. Instead of disentangling the individual pieces of the
problem, the only possible solution was to attack the gestalt con-
dition. Although HIV, stress, and cognitive impairment have been
studied, just like the Gordian knot, their interconnectedness has
created a clinical problem in which teasing out what mechanisms
contribute to the pathophysiology present is fraught with difﬁculty.
Here we discuss what is known about this “Gordian knot” and
debate the question of whether the best path forward is the study
of the whole interconnected condition or continued attempts to
isolate the individual components. We also evaluate the converging
mechanism of inﬂammation, whichmay be driving the relationship
between these three intertwined conditions. What is the best path
forward to develop appropriate therapies to address the co-morbid
and overlapping neuropathology of HIV, stress, and cognitive
impairment with the added complexity of aging?2. Main characters: biology of HIV infection
Although no longer in the spotlight of the worldmedia, new HIV
infections remain rampant, with 50,000 newly diagnosed peopleper year in the United States and 2.3 million people diagnosed
world-wide each year (Committee on Review Data Systems for
Monitoring and Institute of, 2012). Fortunately, the advent of ART
dramatically reduced acquired immune deﬁciency syndrome
(AIDS)-related mortality, such that approximately 30 million peo-
ple currently live with HIV around the globe (Hallett et al., 2014).
HIV is a retrovirus that primarily exerts its inﬂuences on the
activated CD4þ T lymphocytes of the immune system. CD4þ T
lymphocytes are known as “helper T-cells”; they are responsible for
producing cytokines necessary for generating an appropriate and
sufﬁcient immune response for clearing pathogens. Although these
are the primary cells infected in HIV, other cells with CD4 receptors
also become infected, such as peripheral mononuclear cells and
dendritic cells. After infecting a cell, the virus is rapidly replicated in
the cells' nucleus; this process is dependent on reverse transcrip-
tase, an enzyme that catalyzes the transcription of viral RNA into
viral DNA that will then be integrated into the host cell's genome.
During the initial infection, the viral load rises, and the hosts' im-
mune system attempts to ﬁght off the virus with a strong induction
of inﬂammatory cytokines and chemokines. The viral load then
decreases due to activation of the innate immune system and
reaches a stable set point. Eventually, for reasons not yet under-
stood, the virus is able to escape the control of the immune system,
replication accelerates, and viral load increases. As viral load in-
creases, more CD4þ T cells become activated and subsequently
infected, ultimately leading to their death. Typically, the clinical
severity of an HIV infection is determined by a patient's viral load
and CD4þ T lymphocyte count. A clinical diagnosis of AIDS is
garnered once the CD4þ T cell count falls below 200 cells/mm3.
This diagnosis is reversible if ART is initiated and leads to reduction
in viral load and a gradual increase in CD4þ T cells. If left un-
checked, the accelerating destruction of the body's immune system
facilitates entry and expansion of opportunistic infections, which
can be fatal (Maartens et al., 2014).
HIV is treated using a combination of antiretroviral medications
that ﬁght the virus. These medications are categorized into one of
six drug classes based on how they attack the virus. The ﬁrst two
drug classes, non-nucleoside reverse transcriptase inhibitors
(NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs),
block or disrupt reverse transcriptase or simply viral replication.
The third drug class, protease inhibitors (PIs), blocks new/immature
HIV from becoming a mature virus that can infect other CD4þ cells.
Fusion inhibitors are the fourth drug class, and these drugs block
the HIV envelope from fusing with the CD4 cell membrane. The
ﬁfth drug class is CCR5 antagonists (CCR5s) or entry inhibitors, and
they block the CeC chemokine receptor type 5 (CCR5) co-receptor
on the surface of CD4þ cells, which ultimately prevents HIV from
entering the cell. Integrase strand transfer inhibitors (INSTIs), the
last drug class, block the insertion of HIV DNA into CD4þ cell DNA.
The guidelines state that ART is recommended for all PLWH to
decrease the risk of disease progression. However, prolonged use of
combinations of ART drugs can lead to drug resistance and, there-
fore, these treatments are often not prescribed until the ﬁrst indi-
cation of immune suppression (Nath and Sacktor, 2006). Notably,
despite the improvements in ART efﬁcacy in terms of suppression
of viral load, the incidence and prevalence of milder forms of HIV-
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and may have even increased among asymptomatic HIV-infected
individuals (Grant, 2008).
3. Setting the stage: interactions of HIV, stress, and cognition
The new complexity presented by increased life expectancy
following HIV infection is the inﬂuence of HIV on normal aging
processes. Aging with HIV appears to create a synergistic state with
heightened co-morbidities including cardiovascular disease and
depression which may contribute to neurocognitive impairment
(Nemeth et al., 2014). Furthermore, despite the availability of ART,
PLWH are not uniformly responsive to treatment (Moniz et al.,
2014), and poor adherence is a primary factor in suboptimal
treatment response (Li et al., 2014). Stress, emotional reactivity, and
avoidant coping behaviors contribute to HIV progression through
increases in nonadherence (Martinez et al., 2012). Additionally,
aging-associated complexities may exacerbate the effects of stress
on nonadherence in PLWH aged 50 and older (Halkitis et al., 2014;
Warren-Jeanpiere et al., 2014; Wu et al., 2014). Notably, cognitive
functioning is a predictor of medication management and non-
adherence (Wagner, 2002; Hinkin et al., 2004), and the strength of
the predictive capacity increases with age (Frain et al., 2014).
A strong relationship exists between psychosocial factors such
as stress and adverse biological outcomes in PLWH (Sledjeski et al.,
2005; Leserman, 2008; Fumaz et al., 2012; Brumsey et al., 2013);
however, a critical gap subsists in our understanding of the
mechanisms responsible for the adverse consequences of stress in
the context of HIV infection. Available evidence from human
investigation suggests that biological factors secondary to psycho-
social exposures may drive the tempo of HIV pathogenesis
(Sledjeski et al., 2005; Leserman, 2008; Fumaz et al., 2012; Brumsey
et al., 2013) and contribute to variability in response to ART
(Martinez et al., 2002; Sledjeski et al., 2005; Mugavero et al., 2009).
For example, depressive symptoms are associated with a greater
decline in CD4þ T-cell count and increased risk of AIDS mortality
(Leserman, 2008). In addition, with the marked progress towards
effective cure strategies for HIV (Thornhill et al., 2015), attention
must be given to the potential impact of stress-related alterations in
physiology on viral reservoir establishment and maintenance.
Given the profound effects of stress on HIV pathogenesis (Capitanio
et al., 2008; Chida and Vedhara, 2009) and treatment response
(Leserman, 2008; Fumaz et al., 2012), it is not unreasonable to
surmise that HIV-co-morbidities such as cardiovascular disease,
neurocognitive complications, osteoporosis, liver disease, and kid-
ney disease (Freiberg et al., 2013) may also be compounded by
stress.
Despite substantive decreases in HIV-associated morbidity and
mortality following the introduction of ART, neurocognitive com-
plications of the disease remain high (Heaton et al., 1995; White
et al., 1995; Sacktor et al., 2002; Giancola et al., 2006; Tozzi et al.,
2007; Heaton et al., 2011). Speciﬁcally, the frequency of the two
less severe HAND classiﬁcations, asymptomatic neurocognitive
impairment and HIV-associated mild neurocognitive disorder, is
high, at 44% (Heaton et al., 2010). Characterization has changed in
the post-ART era such that the cognitive domains most impaired by
HIV shifted frommotor skills, cognitive speed, and verbal ﬂuency to
learning and executive function impairment (Heaton et al., 2011).
An understanding of complex mechanisms underlying HAND,
including the interactive effects of HIV pathogenesis and aging on
cognition, will be critical in the coming decades as the lifespan of
PLWH expands and the proportion living over the age of 50 rises
dramatically (Deufﬁc-Burban et al., 2007; Vance et al., 2014).
Among HIV-infected men, increased age (i.e., over 50) is a sig-
niﬁcant risk factor for HIV-associated dementia (HAD) (Valcouret al., 2004). By contrast, there is relatively little known about
HAND in HIV-infected women, though HIV-infected women may
be at increased risk for cognitive decline due to the high prevalence
of psychosocial and mental health problems, substance abuse,
lower cognitive reserve due to lower education and pre-morbid
intelligence (Maki and Martin-Thormeyer, 2009), and increasing
age (Basso and Bornstein, 2000; Farinpour et al., 2003). From 1988
to 1997, only 9.3% of research participants in HIV-related neuro-
cognitive studies were female (Fox-Tierney et al., 1999). Although
few studies had sufﬁcient numbers of women to assess neuro-
cognitive complications of HIV, rates of cognitive impairment
within smaller samples of women in the Women's Interagency HIV
Study (WIHS) were high (42%) (Richardson et al., 2002). Important
new data from a landmark study (Cysique and Becker, 2015; Maki
et al., 2015) in the WIHS revealed that the cognitive domains
impacted in women living with HIV are distinct from those
impacted in HIV-infected men (Heaton et al., 1995, 2011). Although
HIV-infected women did not show signiﬁcant neurocognitive
impairment on commonly used measures of executive function,
including the Stroop Trial 3 and Trail Making Test Part B, complex
attention, and learning, women living with HIV demonstrated
profound deﬁcits in verbal memory and simple measures of
attention/concentration (Maki et al., 2009). Consistent with these
epidemiological ﬁndings, neuroimaging ﬁndings in the WIHS also
link hippocampal functioning to verbal memory deﬁcits in HIV-
infected women (Maki et al., 2009). Notably, across multiple
studies certain factors have been identiﬁed that are differentially
associated with verbal learning and memory impairments in HIV-
infected women compared to HIV-uninfected women, including
anxiety and perceived stress (Rubin et al., 2014, 2015a). Post-
traumatic stress is also related to impaired verbal learning and
memory, particularly in HIV-infected women with a history of
sexual abuse and/or physical violence (Rubin et al., 2015c). The
stress-related memory deﬁcits may be partially accounted for by
prefrontal cortical atrophy in HIV-infected women (Maki et al.,
2009; Rubin et al., 2015b). To date, the data collectively suggest
that the neurobiological underpinnings of cognitive deﬁcits diverge
between men and women and that stress may serve as a more
salient trigger in women.
4. Inﬂammation as the director
As discussed in subsequent sections, the immune system ap-
pears to be the primary connection between HIV, stress, and
cognition. Upon HIV infection, numerous cytokines, such as
interleukin-2 (IL-2) and interleukin-6 (IL-6) are produced and an
inﬂammatory state is established. These speciﬁc cytokines lead to
glucocorticoid resistance, causing an elevated basal level of cortisol
in PLWH. This increase in basal cortisol concentrations, compared
to healthy controls, and the elevated presence of cytokines are
hypothesized to contribute to HIV-infected individuals' suscepti-
bility to mood and anxiety disorders as well as cognitive disorders
both individually (Seilhean et al., 1997; Rostasy et al., 2000;
Tiraboschi et al., 2015) and through interactions among the gov-
erning systems (Snyder, 2013; Scott et al., 2015). Thus, the inﬂam-
matory response may be the key in understanding how stress, HIV,
and aging synergize.
4.1. HIV and inﬂammation
The advent of readily available ART has unveiled HIV-related
complications independent of viral replication. One of the current
focuses of HIV research is the constant inﬂammation throughout
the infection. IL-6 is a cytokine that mediates a strong pro-
inﬂammatory systemic response. Middle to older adults (45e76
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higher concentrations of IL-6 in circulation compared to age-
matched controls (Neuhaus et al., 2010). The same study by
Neuhaus et al. (2010) also found that PLWH had an increased
amount of high sensitivity C-reactive protein (hsCRP) in circulation,
another clinically signiﬁcant indicator of systemic inﬂammation.
Additionally, PLWH on ART have been shown to have persistent T-
cell activation despite adequate reduction of viral replication (Hunt
et al., 2003). Elevation of IL-6, hsCRP, and T-cell activation all sug-
gest a systemic state of high inﬂammation during HIV despite ART
(Deeks et al., 2013).
One of the hypotheses regarding systemic inﬂammation due to
HIV infection suggests the gut mucosa is the main source of
inﬂammation. The epithelial mucosa of the gut contains the gut-
associated lymphoid tissue (GALT), home to many HIV-
susceptible CD4þ T cells (Brenchley et al., 2004; Mehandru et al.,
2004). Direct infection of lymphocytes in the gut leads to epithe-
lial injury. Loss of integrity in the gut mucosal layer leads to chronic
exposure to microbial products, such as lipopolysaccharide (LPS)
found on the outer membrane of E. Coli common to the digestive
tract, contributing to systemic inﬂammation (Brenchley et al.,
2004).
Not only are PLWH in a chronic state of inﬂammation, but they
are also in a state of hypercoagulability, reﬂected by an increased D-
dimer level (Neuhaus et al., 2010). The evidence of increased
inﬂammation and hypercoagulability in PLWH seem to offer an
explanation as to why they are more likely to suffer from cardio-
vascular disease (i.e. myocardial infarction and ischemic heart
disease) (Obel et al., 2007; Triant et al., 2007; Nordell et al., 2014). It
is important to emphasize that this state of inﬂammation in PLWH
is independent of viral load (Ronsholt et al., 2013). Although com-
bined ART initially lowers systemic tumor necrosis factor alpha
(TNFa) (Aukrust et al., 1999), another cytokine important for in-
ﬂammatory response, TNFa levels recover and can increase beyond
initial levels, remaining elevated compared to controls even after
12 years of ART (Ronsholt et al., 2013). This further demonstrates
that while established ART regimens can suppress viral load, they
cannot suppress inﬂammation associated with HIV infection. The
source of this ongoing inﬂammation is a current area of study and a
barrier to curing HIV because activated T cells are easily infected,
such that any interruption in ART will result in viral replication due
to the primed T cells. Further, HIV-associated inﬂammation is hy-
pothesized to be the cause of non-AIDS HIV-co-morbidities such as
cardiovascular disease, cancer, and neuropsychiatric disorders.
4.2. Stress, HIV, and inﬂammation
The degree of inﬂammation present in PLWH may be correlated
to psychological stress. A strong correlation exists between IL-6 and
psychological stress as well as mood and anxiety disorders (Fumaz
et al., 2012). PLWH have a higher rate of current and lifetime major
depression, which can be precipitated by chronic stress, compared
to the general population (Atkinson and Grant, 1994; Dew et al.,
1997). Additionally, post -traumatic stress disorder (PTSD) has a
greater prevalence amongst HIV-infected individuals with a range
of 5e74% compared with 7e10% prevalence in the general popu-
lation (Sherr et al., 2011). Anxiety and depression appear to be
associated with the symptomatology (fever, persistent diarrhea,
night sweats, thrush, shingles, upper respiratory infections, fatigue,
lymphadenopathy, and muscle joint pain) of the virus versus the
degree of immunodeﬁciency (Penedo et al., 2003b) and are more
prevalent in women than men (Brief et al., 2004; Robertson et al.,
2014). Furthermore, cognitive behavioral stress management
(CBSM) intervention in PLWH has been shown to decrease reported
distress (Schneiderman, 1999), as well as self-reported levels ofanxiety, depression, anger, and confusion (Antoni et al., 2000a,
2000b). This form of stress management also helps to reduce
physiologic reports of stress as measured by reduced cortisol urine
output (Antoni et al., 2000a, 2000b). Inability to effectively cope
with stress has been correlated with poorer outcomes of psycho-
logical distress and maladjustment to HIV infection (Grassi et al.,
1998). Individuals with maladaptive techniques for coping with
stress, such as illicit substance use and avoidance, have greater
psychological distress than patients who cope using methods such
as positive reframing and acceptance (Lutgendorf et al., 1998;
Penedo et al., 2003a, 2003b). Collectively, these and other studies,
demonstrate a strong association between stress and HIV.
Acute stress has been shown to lead to increases in peripheral
inﬂammation. Across studies, circulating IL-6 and interleukin-1b
(IL-1b) appear to be the most consistently increased following
exposure to acute stress (Steptoe et al., 2007). Increases in in-
ﬂammatory markers in the periphery occur gradually, reaching a
peak concentration at 2-h after the stress has been present
(Rohleder, 2014). The level of inﬂammation caused by acute stress
typically depends on a variety of additional factors, such as: level of
ﬁtness, self-esteem, depressive mood, and loneliness. It has been
suggested that the inﬂammation due to stress may be mediated by
the sympathetic nervous system (Kop et al., 2008). However, the
speciﬁc mechanism as to how acute stress promotes an increase in
peripheral inﬂammatory markers is unknown.
Chronic stress also leads to an increase in inﬂammation. One
inﬂammatory marker that increases with exposure to chronic
stress is TNF-a, which acts downstream to increase oxidative stress,
causing cellular damage (Munhoz et al., 2004). Chronic stress also
promotes inﬁltration of lymphocytes in the small intestine, which
then may lead to other health complications, such as obesity (Lee,
2013). Similarly to acute stress, chronic stress has been demon-
strated to increase the peripheral inﬂammatory cytokine IL-6
(Kiecolt-Glaser et al., 2003), as well as C-reactive protein (CRP)
(Rohleder et al., 2009). A current proposed mechanism to explain
the increase in inﬂammatory markers with chronic stress is
glucocorticoid resistance (Rohleder, 2012). Chronic stress decreases
the levels of glucocorticoid receptors (GR) in the brain, and without
these receptors, glucocorticoids cannot exert their anti-
inﬂammatory effects (discussed in depth below).
Not only does acute stress promote inﬂammation in the pe-
riphery, but the CNS also experiences inﬂammation following
exposure to stress. Acute stress promotes microglial activation in
regions of the brain, including the thalamus, hypothalamus, hip-
pocampus, substantia nigra, and central gray (Sugama et al., 2007).
Interleukin-18 (IL-18) appears to be a cytokine necessary for the
activation of microglia during stress (Sugama et al., 2007). Similarly,
chronic stress can enhance the activation of microglia following a
pro-inﬂammatory stimulus in the CNS (de Pablos et al., 2014).
Treatment with a GR antagonist abolishes the synergistic activation
of microglia following stress and a pro-inﬂammatory stimulus,
suggesting that the receptor mediates the effects of chronic stress
on the immune system (de Pablos et al., 2014). Though acute and
chronic stress may increase inﬂammation in the nervous system
through different mechanisms, it is important to note they both
result in the activation of microglia. Despite the role of microglia in
protecting the nervous system, when activated, they release pro-
inﬂammatory and cytotoxic factors, which can lead to neuronal
death (Kim et al., 2000; de Pablos et al., 2014).
4.3. Cognitive impairment, HIV, and inﬂammation
Neurocognitive deﬁcits are a common feature of HIV/AIDS, and
the frequency and severity of these deﬁcits increase as the disease
progresses. Notably, neurocognitive impairment diminishes quality
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support systems, and the larger community. The cognitive deﬁcits
associated with HAND range from subtle cognitive deﬁcits to
marked dementia syndrome referred to as HIV-associated de-
mentia (HAD) (Heaton et al., 2011). HAND is categorized into three
levels depending on the number of cognitive domains impaired and
the level of interference in everyday functioning. These three levels
include asymptomatic neurocognitive impairment (ANI), mild
neurocognitive disorder (MND), and HAD. A diagnosis of HAND
(least severe level, ANI) requires impairment in at least two
cognitive domains as indicated by performance of at least 1.0
standard deviation below the mean for age and education appro-
priate norms on standardized neuropsychological tests. A diagnosis
of MND additionally requires that the cognitive impairment mildly
interfere with daily functioning (self-reported or observation by
knowledgeable other in work, homemaking, or social functioning).
HAD classiﬁcation requires marked cognitive impairment (2.0
standard deviations below standardized neuropsychological test
norms) and signiﬁcant impairment in daily functioning. For a
proper diagnosis of HAND, all other etiologies explaining the
cognitive disturbance must be ruled out.
HIV viral proteins that are able to cross the blood brain barrier
can lead to the production of cytokines in the neurovascular
endothelium, leading to neuroinﬂammation (Dohgu et al., 2011). As
mentioned previously, HAND is the primary neurocognitive disor-
der in PLWH, which is most likely due to the high levels of neu-
roinﬂammation present. IL-6 levels are increased in the
cerebrospinal ﬂuid of individuals diagnosed with HAND, and
remain increased 12 weeks after starting ART (Airoldi et al., 2012).
Similar to the effects of stress on neuroinﬂammation, HIV exerts
most of its neuroinﬂammatory effects through activation of
monocytes that migrate into the CNS perivascularly. Typically,
activated monocytes express a high level of CD14 on their surface,
but a pro-inﬂammatory phenotype of monocytes with CD16
expression in addition to CD14 exists in about 10% of monocytes
(Belge et al., 2002). This highly pro-inﬂammatory monocyte
phenotype is increased in up to 40% of PLWH (Pulliam et al., 2004).
Though ART has been successful in keeping viral loads low,
maintaining CD4þ T cell levels, and improving cognition in some
cases (Suarez et al., 2001; Sacktor et al., 2009), it has not eliminated
the neurocognitive complications of HIV infection. Prior to ART, the
area most affected by inﬂammation is the basal ganglia. In the
context of ART, the hippocampus, entorhinal cortex, and temporal
cortex are the most affected by inﬂammation (Anthony and Bell,
2008). While there has been a signiﬁcant drop in the rate of HAD
with the advent of ART, rates of mild-to-moderate neurocognitive
impairment remain high (Heaton et al., 2011). HIV-related cognitive
deﬁcits are believed to persist in the post-ART era for various rea-
sons including poor penetration of the CNS, drug resistance, poor
medication adherence, and astrocytes serving as viral reservoirs
(Kramer-Hammerle et al., 2005; Cysique and Brew, 2009). The HIV
virus penetrates the CNS in the early stages of disease (Clements
et al., 2002) and once this occurs, the virus cannot be eliminated
from infected microglia and astrocytes due to the long lifespan and
low turnover of these infected cells (Nath and Sacktor, 2006). Many
ART therapy medications are unable to effectively enter the CNS
due to poor penetration of the blood brain barrier, and in some
cases, the subtherapeutic levels of the drug that do enter can cause
the development of resistant viruses (Ellis et al., 2000; Price and
Deeks, 2004). Advances have been made in determining which
drugs are most effective in penetration of the blood brain barrier
(Best et al., 2011; Decloedt et al., 2015) and in some cases these
diminish neuroinﬂammation (McComsey et al., 2012; Calza et al.,
2016); however, neuropsychiatric and neurocognitive difﬁculties
remain challenges for PLWH (Spudich, 2014).Although there has been a decrease in HAD, the increase and
persistence of HAND in the era of ART suggests that another
mechanism aside from viral replication and infection is responsible
for the neurocognitive deﬁcits present in HIV. One working hy-
pothesis regarding the mechanism for neurocognitive dysfunction
in HIV is that HIV infection activates macrophages and microglia in
the CNS, which then release cytoxins, leading to neuronal and
astrocyte injury (Kaul et al., 2001). It is important to note that HIV
only infects microglia and macrophages; the virus does not infect
neurons. The presence of macrophages and microglia has been
shown to be more strongly correlated with HAD compared to the
presence of HIV-1 virus (Glass et al., 1995). Once the microglia in
the CNS become activated, they release inﬂammatory cytokines,
chemokines, and excitotoxic substances (Lipton and Gendelman,
1995). All of these released substances may damage neurons,
contributing to the pathology found in HAD (Glass et al., 1995). A
potential intrinsic feature of HIV that leads to the activation of
monocytes and microglia is the gp120 envelope protein (Lipton,
1992). Additionally, gp120 and pro-inﬂammatory cytokines can
lead to the production of reactive oxygen species (ROS), which leads
to damage of DNA and RNA. Higher levels of ROS have been
observed in the CNS of HIV patients with HAND compared to
control HIV patients without HAND as well as control non-infected
patients (Zhang et al., 2012). Thus, even with the maintenance of
normal CD4þ T cells and lower viral count with ART, the gp120
protein that is also expressed in infected cells will contribute to the
activation of macrophages and monocytes in the CNS, leading to
cell death and ultimately neurocognitive deﬁcits.
5. Supporting cast: mechanisms linking HIV, stress, and
cognitive impairment
5.1. Sympathetic nervous system
When an individual is under stress, the autonomic nervous
system activates its sympathetic branch to release norepinephrine
and epinephrine. Norepinephrine and epinephrine work on their
target organs to produce awide range of physiologic effects, such as
increasing heart rate, stimulate sweat secretion, and dilation of
bronchioles. Studies on psychological stress on the autonomic
nervous system focus on heart rate variability (HRV) as an indicator
of autonomic nervous system dysfunction. Furthermore, these
particular studies typically focus on work-related stress as a model
of chronic psychological stress. These stress studies have demon-
strated that workplace stressors lead to a decrease in para-
sympathetic nervous system's effect on the heart; leading to an
imbalancewith the sympathetic nervous systemprimarily affecting
the heart rate (Jarczok et al., 2013). Thus, chronic psychological
stress leads to an imbalance of the two components of the auto-
nomic nervous system: the sympathetic nervous system and
parasympathetic nervous system. Such dysregulation of the auto-
nomic nervous system from chronic stress can have signiﬁcant ef-
fects on an individual's health, speciﬁcally in regard to
cardiovascular disease; a decrease in parasympathetic-mediated
HRV is associated with an increased risk of cardiovascular disease
(Thayer et al., 2010).
Additionally, the autonomic nervous system has been demon-
strated to affect the immune system (Severn et al., 1992; Hasko
et al., 1995; Elenkov et al., 2000). Upon treating mice with an
alpha 2 adrenoreceptor antagonist prior to LPS injection, plasma
levels of TNF-a were decreased while IL-6 levels were increased
compared to non-treated animal controls (Hasko et al., 1995).
Furthermore, epinephrine and a beta-adrenergic agonist prevented
the production of TNF-a following LPS stimulation in human blood
samples (Severn et al., 1992). Beta-adrenergic agonists have also
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peripheral blood mononuclear cells following LPS stimulation
(Mizuno et al., 2005). Together, these studies suggest that the
autonomic nervous system plays a modulatory role on the immune
system and inﬂammation.
Autonomic nervous system dysfunction has been demonstrated
as a neurologic complication of HIV infection (Craddock et al., 1987)
and in individuals whose HIV status progresses to AIDS (Becker
et al., 1997). In a cohort of 102 PLWH, 61% of individuals demon-
strated autonomic dysfunction with a score greater than 3 on the
composite autonomic severity score (Robinson-Papp et al., 2013).
Similarly, individuals whose HIV status progresses to AIDS
demonstrate a reduction in HRV (Becker et al., 1997), an effect
similar to the reduction in HRV as a result of chronic psychological
stress. Notably, ART usage signiﬁcantly reduces the occurrence of
autonomic dysfunction (Correia et al., 2006). However, in in-
dividuals on ART, the level of viral suppression does not affect the
occurrence of autonomic dysfunction. PLWH on ART with an un-
detectable HIV viral load have the same occurrence of autonomic
dysfunction as individuals on ART with a detectable load (Chow
et al., 2011). Despite the strong evidence of autonomic dysfunc-
tion associated with HIV infection, the mechanism behind the
pathogenesis is unknown.
5.2. Hypothalamicepituitaryeadrenal (HPA) axis
In addition to the sympathetic response to stress, the HPA axis
serves as the second mediator of the body's response to a stressor.
The end point of this endocrine pathway is for cortisol to be
released by the adrenal cortex. Once cortisol binds to GR, a tran-
scription factor, the receptor allows for a multitude of downstream
effects, including gluconeogenesis, metabolism of fat, protein and
carbohydrates, and suppression of the immune system. Cortisol
exerts a negative feedback effect on receptors in the hypothalamus
and pituitary to stop its own production. Cortisol also inﬂuences
other brain regions including the hippocampus and prefrontal
cortex (PFC), which are critical to cognitive functioning, particularly
to verbal memory performance (Buckner et al., 2000; Dickerson
and Eichenbaum, 2010).
Although the HPA axis is efﬁcient in handling acute stress,
chronic stress may cause long-term changes in the axis. In various
human and animal studies, chronic exposure to stress has been
demonstrated to increase the basal levels of cortisol, as well as
secretion levels in response to acute stress (Lupien et al., 2009). The
primary hypothesis to explain this increase in basal cortisol sug-
gests that down-regulation of glucocorticoid receptors or reduced
sensitivity of the receptors leads to a disruption in negative feed-
back. This hypothesis will be further explained later on.
Studies have shown HIV-infected individuals, predominately
men, have higher cortisol levels compared to non-infected controls
(Membreno et al., 1987; Chrousos and Zapanti, 2014). Other ste-
roids produced by the adrenal glands, such as corticosterone,
deoxycorticosterone, and 18-hydroxycorticosterone remain at
levels similar to those in non-infected controls (Membreno et al.,
1987). Despite these normal levels in PLWH, administration of
cosyntropin, a synthetic derivative of adrenocorticotropic hormone
(ACTH), does not cause the same magnitude of increase seen in
HIV-uninfected individuals (Membreno et al., 1987). This suggests
that alterations in the pathway occur due to actions of HIV
infection.
One of the theories regarding HIV's effect on the HPA axis fo-
cuses on cytokine signaling leading to stimulation of target organs
in the hormone pathway. As discussed earlier, HIV leads to eleva-
tion of circulating inﬂammatory cytokines. One speciﬁc cytokine
implicated in the pathogenesis of HPA dysfunction in the context ofHIV is interlukin-1 (IL-1). IL-1 has the ability to stimulate the hy-
pothalamus and cause the secretion of corticotropin-releasing
hormone (CRH) (Bernton et al., 1987; Sapolsky et al., 1987), which
will lead to downstream activation of the HPA axis and eventual
cortisol release. Alternatively, it has also been suggested that a key
protein on the viral coat, gp120, may mediate the increase in CRH,
rather than mechanisms directly through the immune system
(Costa et al., 2000). Not only does IL-1 stimulate the HPA axis, but
two other key cytokines mediate a similar response including IL-6
and TNF-a. Both of these cytokines help to mediate an increase in
plasma levels of ACTH (Perlstein et al., 1993). As discussed earlier,
there is systemic inﬂammation present in patients regardless of
successful ART; this systemic inﬂammation leads to increases in IL-
6 and TNF-a, promoting the stimulation of ACTH secretion and
eventual elevated levels of cortisol.
Although the speciﬁc mechanism remains to be elucidated, it
can be said that infection with HIV leads to alterations in the HPA
axis, causing an observable increase in cortisol secretion levels.
Even if this pathology is due to stimulation of the pathway through
cytokines versus gp120 on the HIV viral coat, successful ART cannot
prevent HPA axis dysfunction. Both HIV and stress lead to increased
basal cortisol secretion; however, the mechanisms in which these
two conditions cause a similar clinical phenomenon may be
distinct. Where these two pathways converge to both produce
elevated cortisol secretion will be better discussed with regard to
the GR.
5.3. Glucocorticoid receptor
The GRmediates the effects of cortisol on its target organs. Once
cortisol binds to the receptor, it translocates to the nucleus and
serves as a transcription factor. Additionally, activation of the re-
ceptor contributes to negative feedback on the HPA axis. Chronic
stress has been demonstrated to affect the expression of the GR by
decreasingmessenger RNA levels of the GR in speciﬁc brain regions,
such as the hippocampus, cerebellum, and frontoparietal cortex
(Herman et al., 1995; Kitraki et al., 1999). With lower levels of GR
present in the brain, there is insufﬁcient negative feedback, and
cortisol levels are able to increase above normal physiological
levels.
The increase in cortisol levels in a subset of individuals with HIV
may be due to altered characteristics of the GR. These patients have
elevated cortisol and ACTH, but peripherally appear to be in a hypo-
cortisol state with weakness, weight loss, hypotension, and hypo-
natremia. This particular clinical picture of PLWH has been shown
to be due to a reduced afﬁnity of GR on mononuclear cells to its
ligand, leading to a glucocorticoid-resistant state (Norbiato et al.,
1992, 1998). Additionally, the lower afﬁnity of GR leads to an in-
crease in its expression in an attempt for compensation (Norbiato
et al., 1992; Kino and Chrousos, 2004). The inﬂammatory state
intrinsically present in HIV infection may also cause the decreased
afﬁnity of GRs, and thus the glucocorticoid-resistant state. The
combined presence of IL-2 and interleukin-4 (IL-4) has been shown
to lead to the change in GR-binding afﬁnity and increase in GR
number in peripheral blood mononuclear cells (Kam et al., 1993).
Alternatively, structural protein viral protein r (Vpr) of HIV has been
implicated in potentiating GR signaling. Vpr acts as a co-activator of
GR and may lead to glucocorticoid hypersensitivity (Kino and
Chrousos, 2004).
Although stress and HIV infection have seemingly opposite ef-
fects on the GR, with stress decreasing its expression and HIV
increasing it, the end result is similar in both situations. Both HIV
and stress ultimately lead to a glucocorticoid-resistant state in
which receptors are unable to transduce cortisol's signal to the
nucleus and act as a transcription factor. The effect on the GR under
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changes in the HPA axis.
6. A twist in the plot: negative glucocorticoid effects
independent of inﬂammation?
Glucocorticoids impact a broad range of systems, and not all
deleterious effects of glucocorticoids are the indirect result of
inﬂammation. Uncontrollable stress, chronic stress, and stress
hormones also affect cognitive abilities reliant on the hippocampus
and PFC. A clinical study by Lupien et al. (1998) sought to explore
the relationship between cortisol and hippocampal volume, as well
as the subsequent cognitive effects in non-HIV infected patients.
They found that increased cortisol levels were associated with a
reduction in hippocampal volume and impaired hippocampus-
dependent memory. The same group also observed that declara-
tive memory is impaired in elderly subjects upon exposure to a
stressful condition (Lupien et al., 1997). More so, they found that
the subjects who had the affected declarative memory, “re-
sponders”, had an earlier increase in cortisol prior to the stress
event compared to “nonresponders”. These clinical studies
demonstrate that stress affects cognition at the level of the hip-
pocampus, leading to effected spatial and declarative memory.
Pharmacological administration or suppression of glucocorticoids
also affects performance on tasks dependent on the hippocampus
(e.g., verbal memory) and/or PFC (e.g., verbal and working mem-
ory) (Lupien et al., 1999; Henckens et al., 2011; Terfehr et al.,
2011a,b; Henckens et al., 2012).
Numerous rodent studies have observed that high levels of
exposure to glucocorticoids lead to degeneration of the hippo-
campus, and ultimately spatial learning deﬁcits (Landﬁeld et al.,
1981; Issa et al., 1990). In the PFC, chronic stress and
corticosteroid-induced stress can cause dendritic shortening and
atrophy (McEwen, 2007). Studies point to decreased synaptic
plasticity as a potential mechanism for how stress affects the hip-
pocampus (Diamond and Rose, 1994; Gerges et al., 2004; Zoladz
et al., 2012). The speciﬁc pathway that appears to be affected is
long-term potentiation (LTP), as evidenced by reduced levels of
CaMKII. CaMKII is a serine/threonine-speciﬁc protein kinase that
has been heavily implicated in LTP through promotion of dendritic
spine and synapse formation. In these studies, decreased perfor-
mance in a spatial memory task following exposure to stress was
associated with lower CaMKII, especially its active phosphorylated
form. However, it remains to be elucidated if the increased cortisol
from stress causes the lower amounts of p-CaMKII or if some other
mechanism present in chronic stress, such as increased inﬂam-
matory substrates, leads to the impaired LTP.
Further complicating the elucidation of the relationship be-
tween glucocorticoids and cognitive function is the divergence of
impact between men and women. Cortisol has been shown to be
negatively associated with cognition in women but not in men. For
example, 12-h free cortisol excretion is associated with poorer
delayed verbal recall in women but not men in a community based
sample of older adults. Furthermore, women who showed longi-
tudinal increases in cortisol over a 2.5-year period were more likely
to show declines in memory compared with womenwho exhibited
no increases in cortisol over time (Seeman et al., 1997). In a sub-
sequent study, a sex difference was observed in that the effects
following a psychosocial stressor such that cortisol levels correlated
negatively with memory and not mental rotations in women but
not men (Wolf et al., 1998). Finally, a similar effect was observed on
the Wisconsin Card Sorting Task, a prefrontal task. Cortisol levels
before test performance correlated negatively with performance in
women and positively with performance in men (McCormick et al.,
2007). Collectively, these data demonstrate a relationship betweenstress/glucocorticoids and cognitive function, but they do not rule
out the possibility of inﬂammatory mechanisms playing a role in
the relationship because inﬂammatory markers were not assessed
in the studies.
7. Can stress, cognitive impairment, and HIV be disentangled
from each other, or from inﬂammation? Do they need to be?
Given the inter-relatedness of the stress, inﬂammatory mecha-
nisms, HIV, and cognitive impairment, future work will either need
to address classiﬁcation of any two endpoints or embrace the
philosophy that breaking the aberrant cycle at any one point will
subsequently remedy the other related systems and processes.
Such a single-point intervention may be effective in early disease
states, but after perpetuation of an aberrant cycle, adaptations in an
attempt to internally resolve the issue will likely lead to the need
for multifaceted interventions.
Acknowledging that HIV, inﬂammation, and stress may interact
with one another and collectively impact cognitive ability is an
important step in fully understanding an individual's complete
clinical picture. Looking to the future of personalized medicine, it is
important to recognize that if the gestalt condition is not treated,
the underlying system targeted should be tailored to the individual.
For instance, if a PLWH has an extensive history of early life trauma,
they are likely to have an exaggerated inﬂammatory response and a
poorly responsive HPA axis (Neigh et al., 2009). If this person pre-
sents with cognitive impairment, it could be a result of the elevated
inﬂammation, but that inﬂammation would be secondary to both
the HIV infection and the physiological adaptations caused by early
life stress. Although the clinical presentation may be similar to
someone without the inﬂuence of early life stress, the underlying
biological substrates would be divergent, which could impact the
efﬁcacy of any one treatment strategy across a diverse population of
individuals. Although HIV is a robust virus, the inﬂuence of the host
on the progression and presentation of co-morbidities of the
infection should not be underestimated. This is clearly illustrated
by the profound sex differences in HIV and cognition discussed
above and echoed by the impact of aging on all systems of the body.
Although further research is required to provide exact answers for
how to best treat the co-occurrence of HIV, stress, and cognitive
impairment, it is essential to raise awareness among both clinicians
and researchers about these intertwined systems and the pervasive
inﬂuence of inﬂammation across these domains.
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